Jagsonpal Pharma
Ticker >

Jagsonpal Pharma share price

Jagsonpal Pharmaceuticals Ltd.

NSE: JAGSNPHARM BSE: 507789 SECTOR: Pharmaceuticals & Drugs  35k   139   16

325.55
-0.05 (-0.02%)
NSE: Today, 12:53 PM

Price Summary

Today's High

₹ 333

Today's Low

₹ 322.05

52 Week High

₹ 514.85

52 Week Low

₹ 273.6

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 860.68 Cr.

Enterprise Value

₹ 746.06 Cr.

No. of Shares

2.64 Cr.

P/E

35.11

P/B

4.81

Face Value

₹ 5

Div. Yield

1.54 %

Book Value (TTM)

₹  67.71

CASH

₹ 114.63 Cr.

DEBT

₹ 0 Cr.

Promoter Holding

68.09 %

EPS (TTM)

₹  9.27

Sales Growth

8.79%

ROE

18.89 %

ROCE

24.15%

Profit Growth

41.72 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year8.79%
3 Year14.29%
5 Year13.35%

Profit Growth

1 Year41.72%
3 Year50.3%
5 Year33.96%

ROE%

1 Year18.89%
3 Year16.62%
5 Year13.09%

ROCE %

1 Year24.15%
3 Year21.6%
5 Year16.81%

Debt/Equity

0

Price to Cash Flow

18.45

Interest Cover Ratio

85.2808716707022

CFO/PAT (5 Yr. Avg.)

1.60284452633258

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 68.09 0
Dec 2023 68.48 0
Sep 2023 68.71 0
Jun 2023 68.71 0
Mar 2023 68.71 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 50.2950267404404% for the Past 3 years.
  • Company has been maintaining healthy ROCE of 21.6038075261955% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 85.2808716707022.
  • Company’s PEG ratio is 0.841489195911443.
  • The company has an efficient Cash Conversion Cycle of -6.78868881422829 days.
  • Company has a healthy liquidity position with current ratio of 4.89347430650296.
  • The company has a good cash flow management; CFO/PAT stands at 1.60284452633258.
  • The company has a high promoter holding of 68.09%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 3.85386388201674.

 Limitations

  • The company has shown a poor revenue growth of 14.2884653544822% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 60.14 55.45 60.15 57.83 47.23
Total Expenditure 51.51 50.01 51.52 49.46 43.84
Operating Profit 8.63 5.44 8.64 8.37 3.4
Other Income 1.74 2.56 2 2.27 2.52
Interest 0.18 0.2 0.15 0.22 0.23
Depreciation 0.33 0.48 0.39 0.46 0.41
Exceptional Items 0 0 0 0 0
Profit Before Tax 9.87 7.32 10.09 9.96 5.28
Tax 2.08 1.72 2.61 2.49 1.32
Profit After Tax 7.79 5.6 7.48 7.47 3.96
Adjusted EPS (Rs) 2.97 2.14 2.85 2.85 1.51

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 166.83 158.57 187.95 217.58 236.71
Total Expenditure 157.49 150.04 168.87 192.56 202.56
Operating Profit 9.34 8.53 19.08 25.03 34.15
Other Income 1.43 2.53 4.39 3.43 5.73
Interest 0.75 0.51 0.51 0.29 0.41
Depreciation 1.02 1.13 1.09 1.53 1.21
Exceptional Items 0 0 0 0 -3.46
Profit Before Tax 9 9.41 21.87 26.64 34.81
Tax 1.79 1.54 4.81 7.79 8.09
Net Profit 7.22 7.87 17.06 18.86 26.72
Adjusted EPS (Rs.) 2.75 3 6.51 7.2 10.2

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 13.1 13.1 13.1 13.1 13.1
Total Reserves 91.37 97.93 108.83 119.66 145.79
Borrowings 0 0 0 0 0
Other N/C liabilities 3.12 3.09 1.88 4.49 8.49
Current liabilities 28.19 34.57 40.4 34.14 35.18
Total Liabilities 135.78 148.69 164.2 171.4 202.56
Assets
Net Block 21.64 24.44 25.72 22.6 24.28
Capital WIP 1.89 1.9 0 0 0
Intangible WIP 2.06 0 0 0 0
Investments 0 11.39 12.06 28.86 1.12
Loans & Advances 12.63 14.53 5.66 1.07 0.69
Other N/C Assets 0 0.13 0.29 2.62 4.29
Current Assets 97.56 96.31 120.48 116.25 172.17
Total Assets 135.78 148.69 164.2 171.4 202.56
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 9 9.41 21.87 26.64 34.81
Adjustment 0.33 -0.57 -2.09 -1.4 9.25
Changes in Assets & Liabilities 19.71 4.84 11.59 -11.46 9.88
Tax Paid 1.85 -1.8 -3.15 -6.87 -7.28
Operating Cash Flow 30.9 11.89 28.22 6.91 46.66
Investing Cash Flow -0.83 -11.07 -2.26 -25.78 -57.67
Financing Cash Flow -6.05 -1.82 -6.83 -17.55 -0.46
Net Cash Flow 24.02 -1.01 19.13 -36.42 -11.47

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 68.71 68.71 68.71 68.48 68.09
aresko progressive privat... 20.36 20.36 20.36 20.29 20.18
infinity consumer holding... 0.33 0.33 0.33 0.33 0.33
infinity holdings 25.24 25.24 25.24 25.16 25.01
infinity holdings sidecar... 18.15 18.15 18.15 18.09 17.99
rajpal singh kochhar 4.63 4.63 4.63 4.61 4.58
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 31.29 31.29 31.29 31.52 31.91
authum investment and inf... - - - - 1.46
lincoln p coelho 1.18 1.18 1.18 - 1.17
manish gupta 1.62 1.62 1.62 1.62 1.92
mukul mahavir agrawal 1.77 1.77 1.77 - 1.75
sanjiv kumar dudeja - 1.41 1.41 - 1.40
investor education and pr... 1.56 1.56 1.56 - -
vanaja sundar iyer 2.15 2.15 2.01 - -
acadian emerging markets ... 0.10 - - - -
sanjiv kumar dudeja 1.41 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

  • PresentationQ3FY22 23 Feb 2022
  • PresentationQ2FY24 5 Nov 2023

Company News

Jagsonpal Pharmaceuticals launches ‘QueeZy-ER’9 Mar 2024, 2:45PM Jagsonpal Pharmaceuticals informs about press release8 Mar 2024, 5:19PM Jagsonpal Pharmaceutical launches QueeZy-ER8 Mar 2024, 4:54PM Jagsonpal Pharma - Quaterly Results2 Feb 2024, 5:24PM Jagsonpal Pharma - Quaterly Results2 Feb 2024, 5:24PM Jagsonpal Pharma - Quaterly Results2 Feb 2024, 5:24PM Jagsonpal Pharma - Quaterly Results3 Nov 2023, 1:58PM Jagsonpal Pharma - Quaterly Results3 Nov 2023, 1:58PM Jagsonpal Pharma - Quaterly Results3 Nov 2023, 1:58PM Jagsonpal Pharmaceuticals informs about trading window closure29 Sep 2023, 5:25PM Jagsonpal Pharmaceuticals informs about voting results of AGM1 Sep 2023, 3:12PM Jagsonpal Pharma - Quaterly Results2 Aug 2023, 6:16PM Jagsonpal Pharma - Quaterly Results2 Aug 2023, 6:16PM Jagsonpal Pharma - Quaterly Results23 May 2023, 2:44PM Jagsonpal Pharma - Quaterly Results23 May 2023, 2:44PM Jagsonpal Pharma - Quaterly Results23 May 2023, 2:44PM Jagsonpal Pharma - Quaterly Results8 Feb 2023, 8:08PM Jagsonpal Pharma - Quaterly Results8 Feb 2023, 8:08PM Jagsonpal Pharma - Quaterly Results9 Nov 2022, 7:09PM Jagsonpal Pharma - Quaterly Results9 Nov 2022, 7:09PM Jagsonpal Pharmaceuticals informs about allotment of ESOP 19 Sep 2022, 9:51AM Jagsonpal Pharma - Quaterly Results9 Aug 2022, 7:35PM Jagsonpal Pharma - Quaterly Results9 Aug 2022, 7:35PM Jagsonpal Pharmaceuticals informs about certificate20 Jul 2022, 9:54AM Jagsonpal Pharmaceuticals informs about change in KMPs16 Jul 2022, 3:11PM Jagsonpal Pharmaceuticals informs about letter of offer31 May 2022, 4:34PM Jagsonpal Pharma - Quaterly Results30 May 2022, 6:30PM Jagsonpal Pharma - Quaterly Results30 May 2022, 6:30PM Jagsonpal Pharmaceuticals informs about board meeting4 May 2022, 9:56AM Jagsonpal Pharmaceuticals informs about clarification28 Feb 2022, 4:53PM Jagsonpal Pharmaceuticals informs about investor presentation22 Feb 2022, 10:07AM Jagsonpal Pharmaceuticals enters into agreement with Suvinys Developers18 Feb 2022, 11:37AM Jagsonpal Pharmaceuticals informs about supply agreement 18 Feb 2022, 11:32AM Jagsonpal Pharma - Quaterly Results11 Feb 2022, 1:37PM Jagsonpal Pharma - Quaterly Results11 Feb 2022, 1:37PM Jagsonpal Pharmaceuticals informs about compliance certificate13 Jan 2022, 1:46PM Jagsonpal Pharmaceuticals informs about record date for purpose of interim dividend20 Oct 2021, 1:08PM Jagsonpal Pharma - Quaterly Results19 Oct 2021, 5:25PM Jagsonpal Pharma - Quaterly Results19 Oct 2021, 5:25PM Jagsonpal Pharmaceuticals informs about board meeting12 Oct 2021, 10:04AM Jagsonpal Pharmaceuticals informs about newspaper advertisements7 Sep 2021, 3:43PM Jagsonpal Pharmaceuticals informs about press release16 Aug 2021, 10:09AM Jagsonpal Pharmaceuticals informs about disclosure29 Jul 2021, 1:27PM Jagsonpal Pharmaceuticals informs about clarification12 Jul 2021, 3:35PM Jagsonpal Pharmaceuticals informs about certificate28 Oct 2020, 3:27PM Jagsonpal Pharmaceuticals informs about annual secretarial compliance report 1 Jul 2020, 3:35PM

Jagsonpal Pharma Stock Price Analysis and Quick Research Report. Is Jagsonpal Pharma an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Jagsonpal Pharma and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Jagsonpal Pharma cash from the operating activity was Rs 46.655 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Jagsonpal Pharma has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Jagsonpal Pharma , the EPS growth was 41.7181920495755 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Jagsonpal Pharma has OPM of 14.4271145770846 % which is a bad sign for profitability.
     
  • ROE: Jagsonpal Pharma have a average ROE of 18.8918425927235 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Jagsonpal Pharma is Rs 325.6. One can use valuation calculators of ticker to know if Jagsonpal Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Jagsonpal Pharma

Jagsonpal Pharmaceuticals Limited Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Jagsonpal Pharmaceuticals Limited (JPL) is a leading pharmaceutical company in India that develops and sells a range of branded and generic drugs across various specialties such as antibiotics, anti-inflammatory, and analgesics, among others. The company was founded in 1970 and its headquarters are located in New Delhi, India.

Jagsonpal Pharmaceuticals Limited : Share Price

JPL is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) in India. Its share price has been gradually increasing over the past few years, reflecting the company's strong financial performance and growth prospects. You can find real-time and historical share price data on our website, along with various charts and analysis tools to help you make informed investment decisions.

Jagsonpal Pharmaceuticals Limited : Balance Sheet

JPL's balance sheet is a strong indicator of the company's financial health and ability to weather economic downturns. Our website provides you with comprehensive balance sheet data for JPL, including information on assets, liabilities, and shareholder equity. Additionally, our users can access premium tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach and DuPont analysis to calculate the company's fair value.

Jagsonpal Pharmaceuticals Limited : Annual Report

JPL's annual report provides investors with a detailed overview of the company's financial performance, growth plans, and strategic initiatives. Our website provides you with downloadable versions of JPL's annual reports, as well as other research reports, credit ratings, and investor presentations.

Jagsonpal Pharmaceuticals Limited :  Dividend

JPL has a consistent track record of paying dividends to its shareholders, reflecting the company's strong financial performance and healthy cash flow. Our website provides you with historical dividend data for JPL, along with other key financial metrics such as earnings per share (EPS) and return on equity (ROE), to help you make informed investment decisions.

Jagsonpal Pharmaceuticals Limited : Quarterly Result

JPL's quarterly results provide investors with a more frequent update on the company's financial performance and operational metrics. Our website provides comprehensive quarterly result data for JPL, including information on revenue, profit margins, and earnings. Additionally, users can use our pre-built screening tools to compare JPL's performance against other companies in the pharmaceutical sector.

Jagsonpal Pharmaceuticals Limited : Stock Price

JPL's stock price is influenced by a range of factors including the company's financial performance, industry trends, and macroeconomic conditions. Our website provides real-time and historical stock price data for JPL, along with various charts and analysis tools to help you track the company's performance. Additionally, our platform provides various screening tools to help you find stocks that meet your investment criteria.

Jagsonpal Pharmaceuticals Limited : Price Chart

Our website provides you with comprehensive price charts for JPL, which allow you to track the company's stock performance over various time periods. You can customize the charts according to your preferences, including adding technical indicators and other analysis tools. These charts help long-term investors to understand the stock's movement.

Jagsonpal Pharmaceuticals Limited : News and Concall Transcripts

Our website provides you with the latest news and updates on JPL, including analyst reports, press releases, and management interviews. Additionally, users can access JPL's concall transcripts and earn management's insights on various aspects of the company's performance.

Jagsonpal Pharmaceuticals Limited : Investor Presentations

Our website provides downloads of JPL's investor presentations, which provide a detailed overview of the company's financial performance, growth plans, and strategic initiatives. These presentations are a valuable resource for investors looking to understand JPL's positioning within the pharmaceutical sector and evaluate the potential for future growth.

Jagsonpal Pharmaceuticals Limited :  Promoters

JPL's promoters have a long-standing track record of success within the pharmaceutical industry, and their leadership has been instrumental in driving the company's growth and success. Our website provides downloadable data on JPL's promoter holdings as well as insider trading information.

Jagsonpal Pharmaceuticals Limited :  Shareholders

JPL has a diverse shareholder base that includes institutional investors, retail investors, and individual shareholders. Our website provides data on JPL's major shareholders, as well as information on shareholding patterns, and other key ownership metrics for users to analyse. Additionally, our users can use our pre-built screening tools to compare JPL's ownership structure with other companies within the pharmaceutical sector.

Read More
X